Article
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
PloS one - 1 Jan 2015
Uitdehaag Joost C M, de Roos Jeroen A D M, van Doornmalen Antoon M, Prinsen Martine B W, Spijkers-Hagelstein Jill A P, de Vetter Judith R F, de Man Jos, Buijsman Rogier C, Zaman Guido J R
Abstract excerpt
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance. Preferably, drug combinations are synergistic rather than additive, and, ideally, drug combinations work synergistically only in cancer cells and not in non-malignant cells. We have developed a workflow to identify such targeted synergies, and applied this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.